|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta B and Johnson NW: Systematic review
and meta-analysis of association of smokeless tobacco and of betel
quid without tobacco with incidence of oral cancer in South Asia
and the Pacific. PLoS One. 9:e1133852014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Franceschi S, Talamini R, Barra S, Barón
AE, Negri E, Bidoli E, Serraino D and La Vecchia C: Smoking and
drinking in relation to cancers of the oral cavity, pharynx,
larynx, and esophagus in northern Italy. Cancer Res. 50:6502–6507.
1990.PubMed/NCBI
|
|
5
|
Cooper JS, Porter K, Mallin K, Hoffman HT,
Weber RS, Ang KK, Gay EG and Langer CJ: National cancer database
report on cancer of the head and neck: 10-year update. Head Neck.
31:748–758. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dumache R, Rogobete AF, Andreescu N and
Puiu M: Genetic and epigenetic biomarkers of molecular alterations
in oral carcinogenesis. Clin Lab. 61:1373–1381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Genden EM, Ferlito A, Silver CE, Takes RP,
Suárez C, Owen RP, Haigentz M, Stoeckli SJ, Shaha AR, Rapidis AD,
et al: Contemporary management of cancer of the oral cavity. Eur
Arch Otorhinolaryngol. 267:1001–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chinn SB and Myers JN: Oral cavity
carcinoma: Current management, controversies, and future
directions. J Clin Oncol. 33:3269–3276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferris RL, Licitra L, Fayette J, Even C,
Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF,
Haddad R, et al: Nivolumab in patients with recurrent or metastatic
squamous cell carcinoma of the head and neck: Efficacy and safety
in CheckMate 141 by prior cetuximab use. Clin Cancer Res.
25:5221–5230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: Discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, et
al: Increases of amphiregulin and transforming growth factor-alpha
in serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ishikawa N, Daigo Y, Yasui W, Inai K,
Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel
serological and histochemical marker for lung cancer. Clin Cancer
Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kakiuchi S, Daigo Y, Ishikawa N, Furukawa
C, Tsunoda T, Yano S, Nakagawa K, Tsuruo T, Kohno N, Fukuoka M, et
al: Prediction of sensitivity of advanced non-small cell lung
cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kato T, Daigo Y, Hayama S, Ishikawa N,
Yamabuki T, Ito T, Miyamoto M, Kondo S and Nakamura Y: A novel
human tRNA-dihydrouridine synthase involved in pulmonary
carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki C, Daigo Y, Ishikawa N, Kato T,
Hayama S, Ito T, Tsuchiya E and Nakamura Y: ANLN plays a critical
role in human lung carcinogenesis through the activation of RHOA
and by involvement in the phosphoinositide 3-kinase/AKT pathway.
Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kakiuchi S, Daigo Y, Tsunoda T, Yano S,
Sone S and Nakamura Y: Genome-wide analysis of organ-preferential
metastasis of human small cell lung cancer in mice. Mol Cancer Res.
1:485–499. 2003.PubMed/NCBI
|
|
20
|
Taniwaki M, Daigo Y, Ishikawa N, Takano A,
Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression
profiles of small-cell lung cancers: Molecular signatures of lung
cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
21
|
Oshita H, Nishino R, Takano A, Fujitomo T,
Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y and
Daigo Y: RASEF is a novel diagnostic biomarker and a therapeutic
target for lung cancer. Mol Cancer Res. 11:937–951. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayama S, Daigo Y, Yamabuki T, Hirata D,
Kato T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Phosphorylation and activation of cell division cycle associated 8
by aurora kinase B plays a significant role in human lung
carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishikawa N, Daigo Y, Takano A, Taniwaki M,
Kato T, Tanaka S, Yasui W, Takeshima Y, Inai K, Nishimura H, et al:
Characterization of SEZ6L2 cell-surface protein as a novel
prognostic marker for lung cancer. Cancer Sci. 97:737–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato T, Sato N, Hayama S, Yamabuki T, Ito
T, Miyamoto M, Kondo S, Nakamura Y and Daigo Y: Activation of
Holliday junction recognizing protein involved in the chromosomal
stability and immortality of cancer cells. Cancer Res.
67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki C, Takahashi K, Hayama S, Ishikawa
N, Kato T, Ito T, Tsuchiya E, Nakamura Y and Daigo Y:
Identification of Myc-associated protein with JmjC domain as a
novel therapeutic target oncogene for lung cancer. Mol Cancer Ther.
6:542–551. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takahashi K, Furukawa C, Takano A,
Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, et
al: The neuromedin U-growth hormone secretagogue receptor
1b/neurotensin receptor 1 oncogenic signaling pathway as a
therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taniwaki M, Takano A, Ishikawa N, Yasui W,
Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y:
Activation of KIF4A as a prognostic biomarker and therapeutic
target for lung cancer. Clin Cancer Res. 13:6624–6631. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamabuki T, Takano A, Hayama S, Ishikawa
N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, et al:
Dikkopf-1 as a novel serologic and prognostic biomarker for lung
and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fujitomo T, Daigo Y, Matsuda K, Ueda K and
Nakamura Y: Identification of a nuclear protein, LRRC42, involved
in lung carcinogenesis. Int J Oncol. 45:147–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koinuma J, Akiyama H, Fujita M, Hosokawa
M, Tsuchiya E, Kondo S, Nakamura Y and Daigo Y: Characterization of
an Opa interacting protein 5 involved in lung and esophageal
carcinogenesis. Cancer Sci. 103:577–586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nguyen MH, Koinuma J, Ueda K, Ito T,
Tsuchiya E, Nakamura Y and Daigo Y: Phosphorylation and activation
of cell division cycle associated 5 by mitogen-activated protein
kinase play a crucial role in human lung carcinogenesis. Cancer
Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hayama S, Daigo Y, Kato T, Ishikawa N,
Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Activation of CDCA1-KNTC2, members of centromere protein complex,
involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takano A, Ishikawa N, Nishino R, Masuda K,
Yasui W, Inai K, Nishimura H, Ito H, Nakayama H, Miyagi Y, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kobayashi Y, Takano A, Miyagi Y, Tsuchiya
E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y and Daigo Y:
Cell division cycle-associated protein 1 overexpression is
essential for the malignant potential of colorectal cancers. Int J
Oncol. 44:69–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thang PM, Takano A, Yoshitake Y, Shinohara
M, Murakami Y and Daigo Y: Cell division cycle associated 1 as a
novel prognostic biomarker and therapeutic target for oral cancer.
Int J Oncol. 49:1385–1393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Daigo K, Takano A, Thang PM, Yoshitake Y,
Shinohara M, Tohnai I, Murakami Y, Maegawa J and Daigo Y:
Characterization of KIF11 as a novel prognostic biomarker and
therapeutic target for oral cancer. Int J Oncol. 52:155–165.
2018.PubMed/NCBI
|
|
37
|
Nakamura M, Takano A, Thang PM, Tsevegjav
B, Zhu M, Yokose T, Yamashita T, Miyagi Y and Daigo Y:
Characterization of KIF20A as a prognostic biomarker and
therapeutic target for different subtypes of breast cancer. Int J
Oncol. 57:277–288. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Foltz DR, Jansen LE, Bailey AO, Yates JR
III, Bassett EA, Wood S, Black BE and Cleveland DW:
Centromere-specific assembly of CENP-a nucleosomes is mediated by
HJURP. Cell. 137:472–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dunleavy EM, Roche D, Tagami H, Lacoste N,
Ray-Gallet D, Nakamura Y, Daigo Y, Nakatani Y and
Almouzni-Pettinotti G: HJURP is a cell-cycle-dependent maintenance
and deposition factor of CENP-A at centromeres. Cell. 137:485–497.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu B, Wang Q, Wang Y, Chen J, Li P and Han
M: Holliday junction-recognizing protein promotes cell
proliferation and correlates with unfavorable clinical outcome of
hepatocellular carcinoma. Onco Targets Ther. 10:2601–2607. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Valente V, Serafim RB, de Oliveira LC,
Adorni FS, Torrieri R, Tirapelli DP, Espreafico EM, Oba-Shinjo SM,
Marie SK, Paçó-Larson ML, et al: Modulation of HJURP (Holliday
Junction-Recognizing Protein) levels is correlated with
glioblastoma cells survival. PLoS One. 8:e622002013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li L, Li X, Meng Q, Khan AQ and Chen X:
Increased expression of Holliday junction-recognizing protein
(HJURP) as an independent prognostic biomarker in advanced-stage
serous ovarian carcinoma. Med Sci Monit. 24:3050–3055. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hu Z, Huang G, Sadanandam A, Gu S, Lenburg
ME, Pai M, Bayani N, Blakely EA, Gray JW and Mao JH: The expression
level of HJURP has an independent prognostic impact and predicts
the sensitivity to radiotherapy in breast cancer. Breast Cancer
Res. 12:R182010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shuaib M, Ouararhni K, Dimitrov S and
Hamiche A: HJURP binds CENP-A via a highly conserved N-terminal
domain and mediates its deposition at centromeres. Proc Natl Acad
Sci USA. 107:1349–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
